SCHEMBL6257013

SCHEMBL6257013

Cc1ccc(C(C)(C)C)cc1-n1nccc1NC(=O)Nc1ccc(OC(C)CN2CCOCC2)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.53
TNF P01375 6/20 0.49
MAPK12 P53778 4/20 0.49
MAPK13 O15264 3/20 0.49
MAPK11 Q15759 3/20 0.49
DDR2 Q16832 2/20 0.49
HCK P08631 2/20 0.49
CIT O14578 1/20 0.49
MUSK O15146 1/20 0.49
MAP3K7 O43318 1/20 0.49
RIPK2 O43353 1/20 0.49
STK10 O94804 1/20 0.49
MAP4K4 O95819 1/20 0.49
CHEK2 O96017 1/20 0.49
ABL1 P00519 1/20 0.49
EGFR P00533 1/20 0.49
RAF1 P04049 1/20 0.49
NTRK1 P04629 1/20 0.49
HSPB1 P04792 1/20 0.49
PRKCB P05771 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6165706 0.87 MAPK14 (0.71) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL6257597 0.86 MAPK14 (0.52) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL7855430 0.86 MAPK14 (0.54) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL6573925 0.85 MAPK14 (0.51) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL5618844 0.83 MAPK14 (0.65) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL6578339 0.83 MAPK14 (0.56) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL6575226 0.81 MAPK14 (0.54) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL6576675 0.81 MAPK14 (0.56) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL6263852 0.81 ABL1 (0.51) MAPK14TNFMAPK12MAPK13MAPK11
SCHEMBL6676531 0.80 MAPK14 (0.58) MAPK14TNFMAPK12MAPK13MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408950-A2 METHODS OF TREATING CYTOKINE MEDIATED DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-04-21 EP claimed
WO-2003005999-A2 METHODS OF TREATING CYTOKINE MEDIATED DISEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-01-23 WO claimed
EP-1147104-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2001-10-24 EP claimed
WO-2000043384-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-07-27 WO claimed
EP-1545514-A1 ANTICOAGULANT AND FIBRINOLYTIC THERAPY USING P38 MAP KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-06-29 EP disclosed
WO-2004016267-A1 ANTICOAGULANT AND FIBRINOLYTIC THERAPY USING P38 MAP KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-02-26 WO disclosed
EP-1147104-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2001-10-24 EP disclosed
WO-2000043384-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-07-27 WO disclosed